Andrew A. Nierenberg, MD

Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

  • 83Articles
  • 290.4KReads
  • 1998–2026Active
  • 242Collaborators
  • 1.8KCitations

About

Andrew A. Nierenberg, MD, is affiliated with the Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital and the Department of Psychiatry at Harvard Medical School in Boston, Massachusetts. He has contributed 83 articles to Psychiatrist.com between 1998 and 2026, focusing on topics such as depression, bipolar disorder, suicide, tardive dyskinesia, psychiatry, schizophrenia/schizoaffective disorders, addiction, and complementary and alternative medicine. Frequent co-authors include Maurizio Fava, Jonathan E. Alpert, A. John Rush, Jerrold F. Rosenbaum, and Michael E. Thase.

Publications

JCP
Prevalence of GLP-1 Receptor Agonist Use Among Privately Insured Individuals with Mood Disorders
Brief Report

Prevalence of GLP-1 Receptor Agonist Use Among Privately Insured Individuals with Mood Disorders

June 1, 2026

High fill rates of GLP-1 receptor agonist prescriptions in those with mood disorders could indicate that multimorbidity begets more treatment.
, , , et al
JCP
Estimating the 12-Hour Serum Lithium Level
Original Research

Estimating the 12-Hour Serum Lithium Level

March 3, 2025

Lithium blood tests should be conducted 12 hours after the last lithium dose, but complying with this strict timing is difficult. The authors developed a simple tool to estimate...
, , , et al
JCP
Omega-3 Fatty Acids for MDD With High Inflammation
Original Research

Omega-3 Fatty Acids for MDD With High Inflammation

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.
, , , et al
JCP
Webcast

TD Evaluation and Patient Education

March 9, 2021

In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia, how to observe patients (whether in person or via telemedicine), and how to educate patients and families...
,
JCP
ASCP Corner

Wrestling With Antidepressant Use in Bipolar Disorder

January 19, 2021

The question of whether, and when, antidepressants are appropriate in bipolar disorder is a hotly debated topic. This ASCP Corner article summarizes the key concepts with greatest relevance for...
, ,
JCP
Educational Activity

Evaluating Patients for TD

December 1, 2020

Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity,...
JCP
Educational Activity

Talking With Patients About TD Risk

November 3, 2020

Do you know how to talk with your patients about the risk for tardive dyskinesia? Follow along as Dr Nierenberg offers tips for clear communication.
JCP
Consensus Statement

Revisiting the Use of the AIMS in Tardive Dyskinesia Trials

May 8, 2018

The authors of this consensus statement look at the history of the use of the Abnormal Involuntary Movement Scale in tardive dyskinesia studies and outline the challenges of using...
, , , et al
JCP
Educational Activity

Patients Living With Tardive Dyskinesia

January 25, 2018

A series of 6 brief educational videos featuring expert insight and comments by actual patients and their family members helps people understand the risk factors for TD, recognize the...
,
JCP
Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

, , , et al
JCP
Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

, , , et al
JCP
Educational Activity

Residual Symptoms in Depression: Prevalence and Impact

November 25, 2015

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe